Homogenous Good Outcome in a Heterogeneous Group of Tumors: An Institutional Series of Outcomes of Superficial Soft Tissue Sarcomas
Table 1
S-STS patient demographics, disease characteristics, and management.
= 103
Age, years
Median (range)
55 (15–89)
Sex
Male
48 (46.6%)
Tumor location
Trunk
40 (38.8%)
Lower extremity
39 (37.9%)
Upper extremity
14 (13.6%)
Head and neck
8 (7.8%)
Vulva
2 (1.9%)
Tumor size
5 cm
79 (76.6%)
5 cm
21 (20.4%)
Unknown
3 (3.0%)
Histology
Leiomyosarcoma
37 (35.9%)
MFH1
16 (15.5%)
Liposarcoma
8 (7.8%)
Pleomorphic sarcoma
8 (7.8%)
Myxofibrosarcoma
7 (6.8%)
Angiosarcoma
6 (5.8%)
Other2
21 (20.4%)
Grade
Low
32 (31.0%)
Intermediate
7 (6.8%)
High
56 (54.4%)
Unknown
8 (7.8%)
Stage
I
31 (30.0%)
II
49 (47.6%)
III
22 (21.4%)
Unknown
1 (1.0%)
Surgery, resection
R0
95 (92.2%)
Wide (2 cm)
76 (80%)
Close (2 cm)
19 (20%)
R1
6 (5.8%)
Unknown
2 (1.9%)
Surgery, closure of defect
Skin graft
22 (21.4%)
Flap
14 (13.6%)
Radiation therapy
Preoperative
6 (5.8%)
Postoperative
16 (15.5%)
None
77 (74.8%)
Other3
4 (3.9%)
Chemotherapy
Preoperative
5 (4.9%)
Postoperative
3 (2.9%)
None
95 (92.2%)
Malignant fibrous histiocytoma. Including epithelioid sarcoma, fibrosarcoma, synovial sarcoma, clear cell sarcoma, primitive neuroectodermal tumor (PNET), malignant peripheral nerve sheath tumor (MPNST), and not otherwise specified (NOS). Received after LR prior to excision.